Physician profile
William Carter
NPI 1568493195
$2,711.57
in general payments reported to CMS, 2019-2025
19 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2021: $134 · 2022: $247 · 2023: $426 · 2024: $430 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $656.41 | 2019-2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $498.97 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Lilly USA, LLC | $357.17 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Stryker Corporation | $173.49 | 2025 | Spy-Phi System |
| Elucent Medical | $165.82 | 2021-2025 | |
| Daiichi Sankyo INC. | $163.80 | 2022-2025 | Enhertu |
| Eisai INC. | $116.46 | 2019-2025 | |
| Seagen INC. | $115.42 | 2019-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $109.71 | 2025 | |
| Genentech USA, INC. | $85.19 | 2019 | |
| Gilead Sciences, INC. | $52.47 | 2025 | Trodelvy |
| Hologic Sales and Service, LLC | $51.66 | 2023 | Biozorb, Localizer, Trunode |
| Incyte Corporation | $39.36 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $30.15 | 2022 | |
| Genmab U.S., INC. | $24.07 | 2024 | Tivdak |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.22 | 2019 | |
| Madrigal Pharmaceuticals | $18.64 | 2025 | Rezdiffra |
| Pfizer INC. | $16.31 | 2024 | |
| Taiho Oncology, INC. | $16.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.